Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Shattuck Labs (STTK – Research Report), with a price target of $28.00.
Joseph Pantginis has given his Buy rating due to a combination of factors related to Shattuck Labs’ promising clinical developments and financial stability. Pantginis notes the company’s positive preliminary safety and efficacy data across its SL-172154 program, which has demonstrated early anti-tumor activity and favorable safety profiles in various cancer indications. The potential for these developments has been underlined by significant upcoming milestones expected in the near term. Furthermore, Shattuck Labs’ financial position, bolstered by its recent funding, is anticipated to sustain operations well into 2026, allowing for continued clinical trials and other regulatory advancements.
The analyst’s optimism is also rooted in the impressive objective response rates reported from early trial results, particularly in high-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) patients. The company’s reported 79% objective response rate in frontline HR-MDS patients and a 27% initial complete response rate in TP53+ AML patients are key highlights that suggest the drug’s potential efficacy. Additionally, Shattuck’s ongoing clinical trials show signs of durability in treatment responses, which could lead to successful future development and commercialization, further justifying the Buy rating.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Shattuck Labs (STTK) Company Description:
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company’s product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Read More on STTK:
- Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
- Largest borrow rate increases among liquid names
- Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
- Shattuck Labs prices 4.65M shares at $6.45 in registered offering
- Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
